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Maternal and neonatal immunization were evaluated for their capacity to induce protective
immunity against respiratory syncytial virus (RSV) lower respiratory tract infections in early life.
Murine models were studied by use of a novel recombinant vaccine candidate, designated BBG2Na,
which was derived in part from the RSV (Long) G protein. Maternal immunization resulted in the
passive transfer of high levels of RSV-A antibodies to the offspring, which protected them from
RSV challenge for up to 14 weeks. Indeed, protection correlated with the detection of RSV antibodies
in the serum. Neonatal immunization with BBG2Na induced significant antibody responses even
in the first week of life. Most importantly, these neonatal responses were not inhibited by the
presence of RSV maternal antibodies. Consequently, the combination of maternal and neonatal
immunization with BBG2Na resulted in the continual presence of protective levels of antibodies in
the offspring.
Respiratory syncytial virus (RSV) represents the most com- Among the vaccine strategies currently being explored, the
recombinant fusion protein BBG2Na has interesting properties.mon cause of lower respiratory tract infection in young chil-
dren, most of whom are affected during their first winter season. First, it contains an RSV (Long) G protein fragment (G2Na,
aa 130–230), including a conserved subgroup A–specific pro-RSV disease represents a significant cause of infant morbidity,
since 0.5%–2% of infected infants require hospitalization at a tective epitope [11, 12], and a stretch of amino acid residues (aa
164–176) that are completely conserved in all known humanmedian age of £3 months [1–5]. Infant protection from RSV
thus represents a major public health issue and a challenge that A and B RSV isolates [7, 8]. Second, although not directly
demonstrated for G2Na, the albumin-binding region (BB) ofhas not yet been met. An ideal vaccine should induce protective
immune responses to most if not all circulating strains of both streptococcal protein G is capable of significantly enhancing
the in vivo half-life of fusion partners [13, 14] and thus theirA and B subgroups of RSV, in spite of the significant heteroge-
neity of the G glycoproteins [6–8]. In view of peak RSV- exposure to the immune system; BB also enhances antibody
responses to fused peptides [15]. Third, it is produced by pro-induced hospitalization occurring at a median age of 3 months,
however, protective immunity needs to be already present in karyotic expression in Escherichia coli as a nonglycosylated
protein, thereby circumventing the limitations of the nativethe first weeks and months of life. This period is characterized
by immune immaturity and persistence of maternal antibodies G protein immunogenicity because of its heavy glycosylation
pattern [16]. Last, the strong immunogenicity and protectiveable to interfere with infant vaccine responses. Disease en-
hancement at the time of RSV exposure has also been observed efficacy of BBG2Na were recently demonstrated against intra-
nasal RSV challenge in both adult BALB/c mice and cottonafter immunization of seronegative infants with a formalde-
hyde-inactivated viral vaccine [9, 10]. These obstacles have rats [17]. A potent protective efficacy was demonstrated in mice
against both upper and lower respiratory tract RSV subgroup Aeach interfered with the development of a safe and effective
RSV vaccine. (RSV-A) infection and was maintained for at least 48 weeks.
Importantly, BBG2Na immunization also induced protection
against both homologous and heterologous RSV challenge in
both adult mice and cotton rats [17].
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[17]. The limit of detection for lung tissues was £1.45 log10of neonatal immune immaturity and the presence of high levels
TCID50/g of lung, except where insufficient lung homogenate wasof either postinfection or vaccine-induced RSV-A maternal an-
available. When no virus was detected, actual detection limits weretibodies.
used for statistical analyses. Thus, standard deviations 0 were
occasionally recorded for lung titers of some virus-free animal
groups. Lungs were considered protected when virus titers wereMaterials and Methods
reduced by at least 2 log10 relative to control mice.
Mice. Specific pathogen–free adult BALB/c inbred mice were Statistical analysis. Unless otherwise indicated, significance
purchased from IFFA-CREDO (L’Arbresle, France) and kept un- analyses between results obtained from various groups of mice
der specific pathogen–free conditions. Breeding cages were were done (Stat Graphic; Manujistics, Rockville, MD) by use of
checked daily for new births, and the day of birth was recorded the Wilcoxon rank test. P  .05 was considered insignificant.
as the day the litter was found. Pups were kept with mothers until
weaning at the age of 4 weeks.
Vaccine antigen, viruses, and cells. The recombinant fusion
Resultsprotein BBG2Na was expressed in E. coli and purified as described
[17, 18]. Twenty-microgram doses were used per immunization Efficient transfer of BBG2Na-induced antibodies from moth-
after resuspension in PBS containing 20% Al(OH)3 (Alhydrogel; ers to offspring. Adult female BALB/c mice were immunized
vol/vol; Superfos BioSector, Vedbaek, Denmark) immediately be-
twice with 20 mg of BBG2Na prior to mating. As expected,fore immunization. RSV-A (Long strain, ATCC VR-26; American
strong antibody responses to both BBG2Na and RSV-A wereType Culture Collection, Rockville, MD) propagation in HEp-2
observed, often reaching antibody titers5.5 log10 (figure 1A).cells (ECACC 86030501; European Collection of Animal Cell
When antibody determination was initially done in 3-week-Cultures, Porton Down, UK), along with the production of viral
and control cell ELISA antigens, were as described [18]. old pups of such BBG2Na-immunized mothers, BBG2Na and
Immunization and challenge procedures. Groups of 5–8 mice RSV-A antibody titers were always as high as the titers detected
were immunized intraperitoneally at the ages indicated in the figure in their respective mothers (figure 1A). In contrast, no specific
legends. They were bled at regular intervals to determine vaccine- antibodies were detected in pups of nonimmunized or PBS-
and RSV-specific serum antibody titers. When indicated, a booster immunized control mothers (data not shown). Serial bleeding
immunization was given after an interval of 3 weeks. For maternal of the offspring indicated the prolonged persistence of antibod-
immunization, two vaccine doses were given at a 3-week interval
ies of maternal origin, which progressively declined following
before mating. Offspring were challenged with 105 TCID50 of
a decay slope compatible with a half-life of 2 weeks. RSV-RSV-A by intranasal instillation after anaesthetizing with 2.5 mL/
A antibodies could thus be detected for periods of between 12kg of a 4/1 mixture (vol/vol) of ketamine (Imalgene 500; Rhoˆne
and 20 weeks, depending on the respective maternal antibodyMe´rieux, Lyon, France) and xylazine (Rompun 2%; Bayer, Pu-
titers (data not shown).teaux, France). Challenged mice were sacrificed 5 days after chal-
lenge, coincident with previously characterized peak RSV lung Thus, the strong immunogenicity of BBG2Na allowed the
titers [19]. induction of high titers of RSV-A antibodies in adult female
Quantification of vaccine- and RSV-specific antibodies. BALB/c mice, and the natural transfer of BBG2Na-induced
BBG2Na- and RSV-A–specific IgG and subclass antibodies were antibodies from mothers to pups resulted in the development
determined by ELISA. Briefly, flat-bottomed wells of microtiter of adult-equivalent antibody titers and a prolonged persistence
plates (MaxiSorp; Nunc, Roskilde, Denmark) were coated over- of these maternal antibodies in the offspring.
night at 47C with 50 mL of a 4 mg/mL solution of BBG2Na in
Passive transfer of BBG2Na antibodies from mother to pup
PBS or at 377C and low humidity with 50 mL of RSV-A or HEp-
was further characterized by the comparative analysis of the2 cell protein preparations previously calibrated according to their
subclass distribution of vaccine-specific antibodies in both im-reactivity with relevant reference sera. After washing with PBS–
mune mothers and their 3-week-old pups (figure 1B). IgM and0.05% Tween 20 and blocking with 4% milk solids, serial dilutions
IgA antibodies were below detection levels in both mothersof sera were added and incubated for 2 h at room temperature.
The relevant isotype-specific peroxidase-conjugated goat or rabbit and offspring (data not shown). In contrast, similar high titers
anti-mouse (Zymed Laboratories, San Francisco) was added for 2 of all BBG2Na antibody IgG subclasses were found in both
h at 377C before incubation with substrate. Optical density results mothers and pups, indicating an efficient transfer of BBG2Na
were expressed as antibody titers by reference to a titered reference antibodies of all isotypes.
serum representing a pool of sera from immunized adult mice. As Protective efficacy of BBG2Na-induced maternal antibodies.
the virus stocks contained cellular antigen, anti–RSV-A–specific To assess whether natural transfer of maternal antibodies was
antibody titers of mice infected with RSV-A were calculated by
sufficient to confer protection to the offspring of immune moth-
subtracting anti–HEp-2 optical density values from those of anti–
ers, litters from BBG2Na-immune or control mothers wereRSV-A.
challenged with live RSV-A at various ages between the neona-Animal sample preparation and virus titration. Animals were
tal period (2 weeks) and adulthood (up to 14 weeks). Age-anesthetized as described above and exsanguinated by cardiac
matched immune and control litters were always challengedpuncture. Lung removal, lung homogenate preparation, and virus
titration in the homogenates were done as previously described simultaneously. RSV-A lung titers measured at the peak of
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Figure 1. Efficient transfer of
BBG2Na-induced maternal antibod-
ies from immune mothers to off-
spring. Female adult mice were im-
munized twice at 3-week interval
with BBG2Na (20 mg) before mat-
ing. Offspring were kept with moth-
ers up to weaning at 4 weeks of age.
Results from representative litter are
shown. A, BBG2Na- and RSV-A–
specific serum antibodies were mea-
sured by ELISA at various times (0
 day of birth) in both mother and
pups and expressed as mean antigen-
specific antibody titers; B, IgG iso-
types of BBG2Na-specific antibod-
ies were measured by ELISA at time
of delivery in mothers and at 3
weeks of age in offspring and ex-
pressed as mean vaccine-specific an-
tibody titers.
infection were inversely correlated with the presence of detect-
able RSV-A maternal antibodies (table 1). High lung virus
Table 1. Protective efficacy of BBG2Na-induced maternal antibod-titers (4 log10 TCID50/g) were observed in all control mice
ies.born to nonimmune mothers, irrespective of age at time of
challenge. In contrast, lung protection without detectable virus Age (weeks), RSV-A titer (mean { SD)
was observed for all mice in which maternal antibody titers immunogen No. virus-free/
to mothers Antibody* Lung† no. challengedexceeded 4 log10 . Protection was also observed for all pups of
immune mothers challenged at up to 9 weeks of age, although
2virus was detectable at, or just above, the limit of the assay in
BBG2Na 4.25 { 0.1 1.74 { 0.38‡ 8/8
an increasing number of mice as their ages progressed and their PBS 1.4 { 0.0 4.00 { 0.48 0/5
maternal antibody titers diminished. Surprisingly, significant 4
BBG2Na 5.2 { 0.1 1.46 { 0.03§ 7/7protection was still observed at 14 weeks of age in 4 of 7 pups
BBG2Na 4.8 { 0.1 1.51 { 0.13§ 4/4whose residual levels of maternal antibodies (2.0 log10) were
BBG2Na 3.9 { 0.1 £1.53 { 0.12§ 5/7barely above the cutoff of the ELISA. In contrast, all 5 pups at
PBS 1.4 4.37 { 0.38 0/4
14 weeks possessing no detectable residual maternal antibodies
7
were not protected from RSV challenge. BBG2Na 3.8 { 0.2 £1.51 { 0.13§ 1/4
Thus, lung protection from live RSV-A challenge could be BBG2Na 3.7 { 0.2 £1.53 { 0.10‡ 3/5
PBS 1.4 4.00 { 0.21 0/5achieved early in the neonatal period (2 weeks of age) by
9BBG2Na maternal immunization and natural transfer of anti-
BBG2Na 3.2 { 0.1 £1.87 { 0.29§ 1/3
bodies of maternal origin. Maternal antibody–mediated protec-
BBG2Na 3.2 { 0.1 £1.53 { 0.14‡ 4/7
tion persisted as long as maternal antibodies could be detected PBS 1.4 4.30 { 0.29 0/5
in the offspring of immune mothers: for up to 3 months. 14
BBG2Na 2.0 { 0.2 £2.20 { 0.71§ 1/7Neonatal immunogenicity of BBG2Na. We next wondered
BBG2Na 1.4 3.85 { 0.45 0/5whether the strong immunogenicity of BBG2Na would be suf-
PBS 1.4 4.20 { 0.18 0/5ficient to raise significant immune responses in the neonatal
period. Immunization was thus initiated in 1- and 2-week-old NOTE. Blood samples were taken from offspring of BBG2Na-immune
and control mothers of given age for determination of maternal antibody titers.pups of nonimmune mothers. Interestingly, significant vaccine
Pups were challenged through 3 independent experiments assessing simultane-responses were observed after a single immunization, even in
ously 2- and 4-, 7- and 9-, and 14-week-old pups. Significance was determined
mice that were only 1 week old at time of priming, and reached for each group relative to age-matched naive controls.
* ELISA titer, log10 .high antibody levels after a repeat immunization given 3 weeks
† RSV-A titer, log10 TCID50 /g of lung.later (figure 2A).
‡ P  .001 (t test using null hypothesis).
Comparative analysis of the IgG1 and IgG2a subclass distri- § P  .05 (nonparametric test; Kolmogorov-Smirov test because of low
sample numbers).bution of vaccine-specific antibodies (selected as indirect mark-
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Figure 2. Antibody responses in-
duced by neonatal immunization
with BBG2Na. Mice were primed in
neonatal period or as adults and
boosted 3 weeks later with BBG2Na
(20 mg). A, BBG2Na- (left) and
RSV-A–specific (right) serum anti-
bodies were measured by ELISA
at various times and expressed as
mean antigen-specific antibody ti-
ters; B, IgG1 and IgG2a isotypes of
BBG2Na- (left) and RSV-A–spe-
cific (right) antibodies were mea-
sured by ELISA 1 –2 weeks after
booster and expressed as mean anti-
gen-specific antibody titers.
ers of Th1/Th2 type of responses) induced by BBG2Na immu- mice (figure 2B, right). Thus, IgG2a antibodies are unlikely to
play a significant role in the observed protection. Becausenization in adult or neonatal mice is reported in figure 2B. As
expected in view of our previous observations [20], the IgG2a/ young mice with passively transferred IgG1 maternal antibod-
ies whose titers were significantly lower (2.0 log10) than thoseIgG1 ratio of BBG2Na-specific antibodies (left) was signifi-
cantly lower in neonatally compared with adult-primed mice. induced by neonatal immunization, even in 1-week-old mice
(3 log10), were protected from RSV challenge (table 1), pro-Thus, the isotype pattern of alum-adsorbed BBG2Na-induced
vaccine antibodies is suggestive of a mixed Th1 and Th2 pat- tection studies were not repeated.
Protective levels of maternal antibodies do not inhibit neona-tern in adult mice and of a Th2 bias of vaccine responses on
immunization in early life. However, BBG2Na-induced RSV- tal vaccine responses to BBG2Na. Since the presence of ma-
ternal antibodies is known to exert an inhibitory influence onA antibodies were found exclusively among the IgG1 and not
among the IgG2a isotypes, in both adult- and neonatally primed the induction of vaccine responses in infants, the neonatal im-
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Figure 3. Induction of neonatal
responses to BBG2Na despite pres-
ence of high titers of maternal anti-
bodies. Mice were immunized at 2
weeks of age with BBG2Na (20 mg).
RSV-A–specific serum IgG antibod-
ies were measured by ELISA at regu-
lar intervals and expressed as mean
antigen-specific antibody titers. A,
Immunization was done 48 h after
intraperitoneal transfer of postinfec-
tion RSV-A–hyperimmune serum
(ELISA titer, 5.2 log10) or normal
mouse serum; B, immunization was
performed in pups of either
BBG2Na-immune or nonimmune
mothers as controls.
munogenicity of BBG2Na was evaluated in both the presence tal immunization with BBG2Na is not inhibited by the presence
of protective titers of vaccine-induced RSV maternal anti-and absence of passively transferred antibodies. In a first set
of experiments, we assessed whether passive transfer of high bodies.
titers of RSV-A antibodies induced by repeated RSV infections
would affect the neonatal immunogenicity of BBG2Na. A lot
of hyperimmune (5.2 log10) anti–RSV-A polyclonal serum was Discussion
produced in adult mice by repeat (five times) intranasal instilla-
tion of live RSV-A. An aliquot (200 mL) of this hyperimmune This report provides evidence that immunization with
BBG2Na before pregnancy results in the passive transfer ofserum was experimentally defined as resulting in approximately
mother-like antibody titers after intraperitoneal transfer to 2- high levels of vaccine antibodies to the offspring of immune
mothers, such maternal antibodies protect the lungs of the pupsweek-old mice. Forty-eight hours later, blood samples were
taken from these young mice for antibody determination before against an RSV challenge performed during the neonatal period
and up to 14 weeks later, high levels of vaccine-specific anti-immunization with a single dose of BBG2Na. In contrast to
the natural decay slope of maternal antibodies observed when bodies can be induced by BBG2Na even in the first week of
life, and such vaccine responses can be induced in the neonatalneonatal immunization was not performed (figure 1A), RSV-
A antibodies reached and remained at the same plateau (3.5 period in spite of the presence of high levels of RSV maternal
antibodies.log10) as seen in control mice at all times during the14-week
follow-up period (figure 3A). This observation indicates active A significant proportion of RSV lower respiratory tract infec-
tions, including the most severe, occurs in the first 3 monthsproduction of antibodies by the BBG2Na-immunized pups in
spite of the presence of very high titers of passively transferred of life. This early occurrence of disease and the observation
that RSV antibodies alone can reduce the severity of lungmaternal RSV-A antibodies at time of immunization, and even
without administration of a second vaccine dose at a later time disease (reviewed in [21]) have set the basis for the develop-
ment of novel vaccine strategies targeting women of childbear-point.
In a second set of experiments, we investigated whether ing age rather than young infants. The success of such ap-
proaches is expected to depend on the capacity of vaccineBBG2Na would retain its neonatal immunogenicity even in
the presence of BBG2Na-induced antibodies resulting from candidates to induce high and persistent titers of protective
RSV antibodies in young women and on the efficacy of placen-maternal immunization. Offspring from either BBG2Na-im-
mune or control mothers were immunized with a single dose tal transfer of maternal vaccine-specific antibodies to infants.
These two parameters define the time period during whichof BBG2Na and followed at regular intervals for antibody
determination. Again, when immunization was performed in progressively declining maternal antibodies can be expected
to remain above protective levels in infants. Although thesethe presence of a BBG2Na-induced RSV-A titer of maternal
antibodies previously demonstrated as fully protective (4 log10 , properties can be definitively evaluated only by clinical testing
in humans, we report here in mice the promising preclinicaltable 1), a single dose of BBG2Na induced the same titer of
RSV-A antibodies in pups of either immune or control mothers evaluation of BBG2Na as a candidate for RSV maternal immu-
nization.(figure 3B). Thus, under these experimental conditions, neona-
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The immunogenicity of BBG2Na in adult mice is sufficient lation of BBG2Na antibodies in adult mice [17]. The results
also underline the strong protective capacity of BBG2Na-in-to rapidly induce high and persistent levels of RSV-specific
antibodies capable of conferring protection against homologous duced antibodies, which proved capable of extensive viral
clearance at antibody titers considerably below those associatedand heterologous RSV challenge in the lower respiratory tract
[17]. We show here that the transplacental transfer of BBG2Na- with in vitro neutralization activity [17], through yet-undefined
molecular mechanisms.induced antibodies from immune mothers to their offspring is
so efficient as to result in the achievement of similar RSV-A– Given the transient nature of protection conferred by mater-
nal immunization, protection from RSV disease in early lifespecific antibody levels of all isotypes in mothers and pups.
This immunoglobulin transfer through the FcgRn [22, 23] is is likely to require a sequential approach in which maternal
immunization would be followed by the induction of protectivean active and saturable process that is influenced by several
factors in both mice and humans. The first factor is directly immune responses through neonatal immunization. Although
this could be achieved through the use of different vaccines,related to the level of seric vaccine antibody that can be raised
in adults, which favors the use of adjuvanted recombinant RSV we evaluated the neonatal immunogenicity of BBG2Na. It was
found to induce strong vaccine-specific immune responses evenproteins or fragments compared with the more local action of
intranasally applied live attenuated or mutant viruses. The use in the first week of life, with a 3- to 4-week delay required to
reach an antibody titer 3 log10 . The previously reported Th2of non-live vaccines also offers obvious safety advantages for
immunization of women of childbearing age. bias of neonatal vaccine responses [20, 35–38] is also sug-
gested here by the reduced IgG2a/IgG1 ratio of BBG2Na anti-The second factor affecting transfer of maternal antibodies is
the availability of sufficient time between induction of vaccine bodies observed in neonatally primed mice. In view of the
concerns related to the induction of Th2-mediated RSV re-antibodies in mothers and delivery. If the prolonged persistence
of BBG2Na antibodies (possibly related to the prolonged expo- sponses in infants, which were linked to disease enhancement
at the time of virus exposure [9, 10], we performed a differentsure of the immunogen due to its albumin-binding property)
also occurs in humans, it will allow us to consider the immuni- set of experiments showing that the Th1/Th2 pattern of neonatal
vaccine responses to protein antigens depended essentially onzation of women of childbearing age rather than the more
complex approach of vaccination during pregnancy. The third the choice of the adjuvant formulation: Selection of a Th1-
driving adjuvant could circumvent the preferential Th2 polar-factor is the nature of the vaccine-specific antibodies them-
selves, defined by both antibody isotypes and other as-yet ization of neonatal responses and induce Th1 responses even
in newborn mice if used at time of priming [39]. Similar experi-poorly understood parameters. Here, BBG2Na antibodies of all
IgG subclasses were efficiently transferred from mothers to ments are pursued with BBG2Na. Given the importance of
these concerns, the role of cell-mediated immunity to RSVpups. This is in striking contrast to the reduction in materno-
fetal IgG2b transfer observed in other models of murine mater- after BBG2Na immunization in the presence of alum is now
being studied in terms of both protection and potential pathol-nal immunization analyzed thus far by us (unpublished data)
and others [24, 25], including for RSV antibodies [25]. Whether ogy enhancement.
Passively transferred maternal antibodies have been shownthis efficient transfer of all BBG2Na isotypes is linked to their
recognition of BB, the albumin-binding component of the im- to interfere with the infant capacity to respond to antibody-
specific immunogens. Given the ubiquitous nature of RSV andmunogen, or of the RSV G2Na fragment will be addressed
through maternal immunization studies involving other recom- the frequency of reinfections in adults, RSV antibodies of ma-
ternal origin are present at low to moderate titers in mostbinant fusion proteins.
The protective efficacy in neonates of passively transferred infants. Indeed, the reduced antibody response to F and G RSV
proteins in infants 9 months of age was shown to result frommaternal BBG2Na-induced antibodies was similar to that ob-
served after active immunization of adult mice with BBG2Na both immunologic immaturity and maternal antibody-mediated
inhibition of vaccine responses [40, 41]. In rodent experimentalor RSV-A [17]. It also compared favorably with the protective
efficacy of virion-purified [26–29] or recombinant vaccinia models, passively transferred RSV antibodies have been re-
ported to interfere with immune responses to intraperitonealvirus–expressed RSV G or F proteins or fragments [30–34].
Comparisons between residual maternal antibody titers at vari- infection with live RSV-A [25, 42], to F- and G-expressing
recombinant vaccinia viruses [43], and to F and G glycopro-ous ages and concomitant RSV-A lung virus titers at the time
of challenge allowed us to define the antibody levels associated teins [44]. In contrast, we showed here that even high titers
(5 log10) of postinfection RSV-A maternal antibodies did notwith protection. Complete protection (i.e., no detectable virus
5 days after challenge) was conferred by maternal antibody interfere with the induction of antibody responses to a single
dose of BBG2Na given at 2 weeks of age. An attractive hypoth-levels4 log10 . More important, even barely detectable mater-
nal antibody titers (2.0 log10) were sufficient to confer lung esis is that the immunogenicity of this nonglycosylated G pro-
tein fragment is sufficiently different from the immunogenicityprotection. These observations demonstrate maternal antibody-
mediated protection. They confirm and extend the demonstra- of the native RSV protein equivalent to escape from RSV-A–
specific antibody-mediated inhibition. This could be in contrasttion of protection following intranasal or intraperitoneal instil-
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2. Martin AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral
recombinant vaccinia viruses [43] and reported as susceptible
infection among pediatric inpatients over a six year period in northeast
to passive antibody inhibition. Alternatively, the RSV-A frag- England. Lancet 1978;2:1035–8.
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8. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity
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of the attachment protein of subgroup B respiratory syncytial viruses.
mediated inhibition. Irrespective of the molecular mechanisms J Virol 1991;65:5425–34.
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